清热化痰法对痰热蕴肺型急性肺损伤治疗作用的研究
|
摘要
[背景]急性肺损伤(Acute Lung Injury, ALI)是一种常见而严重的呼吸急症,是指由各种肺内、外致病因素导致的急性进行性缺氧性呼吸衰竭,1967年被Ashbaugh首次报道。该病具有较高的发病率和病死率。其发病机制仍不十分明确,目前认为其发生和发展是多病因共同作用的结果,其中过度失调的炎性反应被认为是最重要的因素之一。临床上尚无特异治疗方法。
中医虽无“急性肺损伤”的病名,但按其临床表现,应属“喘证”、“结胸”“喘脱”、“暴喘”等病的范畴,病位主要在肺和肾。肺失宣降、气机逆乱、毒邪壅滞是发病早期的重要病机,其中的毒邪包括热、毒、痰、瘀等,患者热、毒、痰、喘、瘀、闭的表现突出,宜运用清热解毒、宣肺平喘、豁痰开窍、攻里通下等治法。综合既往研究结果提示,一些以清热解毒或清热化痰为指导原则的中药方剂或中成药经实验验证,对ALI有一定效果。
[目的]通过设立常规治疗、常规治疗加乌司他丁、常规治疗加清热化痰法等三组,对比三组疗效,评价清热化痰法对痰热蕴肺型ALI的临床疗效,并结合动物实验研究其可能的作用机制,另外还探讨痰热清注射液在治疗ALI方面是否存在量效关系及其安全性,为今后更深一步的研究打下基础。
[方法]临床研究采用随机、单盲研究方法。2010年2月至2012年2月期间,从广州中医药大学第一附属医院重症医学科,以及广州市中医医院急诊科、呼吸科纳入的符合标准的病人共计46例。将病人随机分入常规治疗组(A组)、常规治疗加乌司他丁组(B组)、常规治疗加中药组(C组)等三组,三组的治疗方案分别是常规治疗、常规治疗加乌司他丁、常规治疗加清热化痰法,疗程为14天。观察住院期间患者中、西医症候的变化,以及呼吸机使用时间、血清炎症因子、Murray肺损伤评分等指标。
本动物实验以静脉注射脂多糖的方法复制ALI大鼠模型。通过对正常对照组(A组)、急性肺损伤模型组(B组)、乌司他汀对照组(C组)、中药常规剂量组(D组)、中药高剂量组(E组)等各组大鼠分别予生理盐水5ml、生理盐水5ml、乌司他丁(2.1万U/Kg)、常规剂量痰热清(2.1ml/Kg)、高剂量痰热清(4.2ml/Kg),连续给药3天,对照观察各组大鼠的肺组织匀浆中的各项炎症指标、肺湿干重量比、肺病理改变,以及各组死亡率,观察清热化痰法对ALI是否存在治疗作用,并初步探讨其作用机制和安全性。
[结果]临床研究发现,A、B、C三组治疗后的心率、氧合指数、胸片、Murray肺损伤评分等各项指标都较治疗前有明显改善(P<0.05)。而B、C两组又较A组改善明显(P<0.05或P值接近0.05)。B、C两组之间未见明显的差异性(P>0.05)。A组治愈3例,好转5例,未愈3例,死亡3例,总有效率57.14%；B组治愈7例,好转5例,未愈2例,死亡2例,总有效率68.75%；C组治愈7例,好转6例,未愈2例,死亡1例,总有效率75%。但三组间资料比较未见有统计学意义的差异(P>0.05)。在呼吸机通气时间,以及TNF-α、IL-6、MMP-9等指标的比较上,B、C两组均较A组的数值明显降低(P<0.05)。而B、C两组之间则未见明显的差异性(P>0.05)。
动物实验方面,同日不同组之间的比较,C、D、E三组3天的IL-6、TNF-α、MMP-9等炎症指标,以及W/D、病理切片结果均较B组有显著性的改善(P<0.05)；而此三者之间未见明显差异(P>0.05)。同组不同日之间的比较,C3与C1的W/D比较有明显的下降,C2、D2组的TNF-α水平与C1、D1组比较有明显的下降(P<0.05),E3组与E1组的TNF-α水平也有明显的下降(P<0.05),而IL-6、MMP-9则无上述变化。而W/D、肺部切片等在连续给药3天中均有不同程度的逐日改善。不良事件方面,B组在第1天死亡1只,C组在第3天死亡1只,D组在第2天死亡1只,E组大鼠在第1、2、3天各死亡1只。B、C、D三组的死亡率均为5.6%,E组死亡率为16.7%。另外,E组大鼠有半数出现大便溏、次数多的不良反应。
[结论]1、常规治疗、常规治疗加用乌司他丁、常规治疗加用清热化痰法三种治疗方法,均对ALI有一定的治疗效果,体现在患者临床表现、影像学检查和实验室检查等方面的改善。而后二者又比常规治疗效果更佳,体现在后二者使用呼吸机的时间更短,血液中炎症因子含量下降更明显,但后二者之间未见有明显差异。清热化痰法治疗痰热蕴肺型ALI的机制之一是降低患者血清中TNF-α、IL-6、MMP-9等炎症因子的水平。清热化痰法能改善痰热蕴肺型ALI的病情,阻断其向更严重的ARDS发展,缩短呼吸机的使用时间,提高临床疗效。
2、从中医角度评价疗效,常规治疗加用清热化痰法对痰热蕴肺型ALI有一定的疗效,但与单纯西医常规治疗,以及常规治疗加用乌司他丁相比未有统计学意义上的差异,需进行更大样本量的临床观察以进一步研究。另外,在研究中我们发现,加用清热化痰法的病例大多大便偏软,甚偏溏,根据肺与大肠相表里的理论,通便既可降肺气,又可清肺热,因此这可能是清热化痰法治疗痰热蕴肺型ALI的机制之一。所以,可以在辨证使用清热化痰的治法基础上,酌加泻下通便的中药,可能会增加疗效。
3、乌司他丁、常规剂量痰热清、大剂量痰热清均对ALI大鼠有一定的治疗作用,三者的疗效相当,其作用机制是通过降低肺局部TNF-α、IL-6、MMP-9等炎症因子的水平以减轻肺部炎症反应,改善肺部病理改变,从而对ALI大鼠的肺部起到一定的保护作用。
4、与第1天相比,当用药到第2天或第3天时,乌司他丁、常规剂量痰热清、大剂量痰热清三组大鼠的肺匀浆中的TNF-α含量均有明显的下降。TNF-α呈逐日降低的趋势,可能与它是早期主要的前炎症因子之一,是炎性反应中释放最早、最重要的内源性介质有关。
5、连续给药到第2天、第3天, ALI大鼠的W/D和肺部病理切片均较第1天有一定改善,提示连续用药较单纯用药1次可获得更好的疗效。
6、与常规剂量相比,大剂量的痰热清并未能使ALI大鼠获得更好的疗效,反而令该组大鼠的不良反应发生率和死亡率有增高的趋势。
[Background] Acute lung injury (ALI), one of the respiratory system emergency cases, first reported by Ashbaugh in1967, is acute, progressive and hypoxia respiratory failure caused by multiple endo-or ecto-lung etiological factors. ALI has high morbidity and fatality, but its pathogenesis is not fully identified. At present, its genesis and development is regarded as the result of multiple etiological factors. among these, over-imbalance inflammatory reaction is regarded as one of the most important factors. Specific therapy is absent so far.
The name "Acute lung injury" was not exist in TCM, but according to clinical manifestation, ALI pertains to "panting patterns","chest bind","panting desertion" and "fulminant panting", of which position of disease is lung and kidney. The vital and pristine pathogenesis is impairment of dispersing and descending function of the lung, disorder of the activities of qi, and also obstruction of poison of lung. The poison factors include heat, toxin, phlegm and stasis, by which the patients'appearance with heat, toxin, phlegm panting, stasis and blocking is significant. To treat these, the method of treatment, including clearing heat and resolving toxin, diffusing the lung and calming panting, sweeping phlegm and opening the orifices, and precipitation, should be used. The results of previous researches revealed that some formula and Chinese pattern medicines directed by either the principle of clearing heat and resolving toxin or clearing heat and transforming phlegm have a certain extent of curative effect.
[Objective] To evaluate the curative effect for the phlegm-heat-obstructing-the-lung-type ALI of the management of clearing heat and transforming phlegm, we establish the groups of conventional therapy, conventional therapy adding ulinastatin (UTI) and conventional therapy adding clearing heat and transforming phlegm, and compare them. On the other side, we investigate the mechanism of the management of clearing heat and transforming phlegm according to the animal experiment. In additional, we investigate the dose-effect relationship and safety of Tanreqing injection curing ALI for further study.
[Method] We used randomized, single blind methods in clinical research. From February2010to February2012, we collected46patients from the First Affiliated Hospital of Guangzhou TCM University and Guangzhou hospital of TCM, who met the diagnosis criterion of ALI. We randomly divided them into the group of conventional therapy (group A), of conventional therapy adding UTI (group B) and of conventional therapy adding Chinese medicine (group C). The therapeutic regimens of these3groups respectively were conventional therapy, conventional therapy adding UTI and conventional therapy adding clearing heat and transforming phlegm, while their courses of treatment were14days. The patients'symptoms of Chinese medicine and Western medicine, the time of using breathing machine, inflammatory factors in serum and lung injury score (LIS) were observed in the duration of hospital stay.
The rat model of ALI was produced with intravenous injecting lipopolysaccharide. After establishing the group of normal control (group A), of ALI model (group B), of UTI (group C), of normal does of Chinese medicine (group D) and of high does of Chinese medicine (group E), we respectively gave them normal sodium5ml, normal sodium5ml, UTI (21, OOOU/kg), Tanreqing(2. lml/kg) and Tanreqing(4.2ml/kg), for3days consecutively, then compared inflammatory factors in the rats'lung homogenate, the wet weight-dry weight ratio(W/D), pathologic change of lung, and the mortality of each group.
[Result] The result of clinical study revealed that compared to pretherapy, three groups had significant changes in the aspects of breathing rate, heart rate, saturation of blood oxygen, oxygenation index, sternite and LIS after treatment (P<0.05). Generally speaking, the changes of group B and C were more significant then that of group A, while not obvious between group B and C. According to the viewpoint of Chinese medicine, in group A,3patients were cured,5improved,3not cured,3dead, and total effective rate of this group was57.14%; in group B,7patients were cured,5improved,2not cured,2dead, and total effective rate of this group was68.75%; in group C,7patients were cured,6improved,2not cured,1dead, and total effective rate of this group was75%. But no significant difference was observed. In the aspects of duration of ventilation with breathing machine and the inflammatory factors, such as TNF-α, IL-6and MMP-9, group B and C degraded more significantly than group A(P<0.05), while there was no difference between group B and group C(P>0.05).
The result of animal experiment revealed that in the aspect of horizontal comparison of the same day, the indexes, such as TNF-α, IL-6, MMP-9, W/D and pathologic change of lung, of group C, D and E were more significant than those of group B(P<0.05), while no significant difference among group C, D, E(P>0.05). On the other side, in the aspect of longitudinal comparison of the same group, the W/D of C3had more significant decrease than C1,whle significant decrease of TNF-α was present between C2and Cl, D2and D1, E3and El(P<0.05), but no such change of IL-6or MMP-9. During these3days, different extent of improve in W/D and pathologic change of lung was observed day by day. A rat of group B died in the first day, one of group C died in the third day, one of group D died in the second day, while a rat of group E died in everyday. The mortality of group B, C and D was5.6%, while group E was16.7%. Besides, half rats of group E appeared frequent and loose stool.
[Conclusion]1. Conventional therapy, conventional therapy adding UTI and conventional therapy adding the management of clearing heat and transforming phlegm are effective for ALI, reflected in the improve of the patients'clinical performance, imageology examination and laboratory examination. The latter two are better than conventional therapy, for the time of using breathing machine was shorter and inflammatory factors in serum were less, while they had no significant difference with each other. One of the mechanisms of the management of clearing heat and transforming phlegm curing the phlegm-heat-obstructing-the-lung-type ALI is decrease the content of TNF-α, IL-6, MMP-9in serum. It can improve the phlegm-heat-obstructing-the-lung-type ALI, arrest its growth to ARDS, shorten the time of using breathing machine and enhance curative effect.
2. According to the viewpoint of Chinese medicine, conventional therapy adding the management of clearing heat and transforming phlegm has some curative effect for the phlegm-heat-obstructing-the-lung-type ALI, but shows no significant difference with conventional therapy or conventional therapy adding UTI, thus the research of larger sample size is required. In additional, we find the patiens'stool of conventional therapy adding clearing heat and transforming phlegm is soft, or even sloppy. Basis on the theory of "lung and large intestine are exterior and interior", purgation helping downbear lung-qi and clear lung-heat, it is regarded as one of the mechanisms of the management of clearing heat and transforming phlegm. Therefore, it can enhance curative effect by adding the herb for relieving constipation by purgation on the base of the pattern identification and using he management of clearing heat and transforming phlegm.
3. UTI, normal does of Tanreqing and high does of Tanreqing has respectively some curative effect for ALI rats, which has no significant difference with each other. The mechanism is that the content of inflammatory factors such as TNF-a, IL-6and MMP-9in lung is decreased so that the inflammatory reaction is gentler, pathologic change of lung is improved and therefore lung is protected.
4. In the second day and the third day, the content of TNF-α in the rats'lung homogenate from the group of UTI, normal does of Tanreqing and high does of Tanreqing was lower than in the first day. TNF-α displays the trend of day-by-day decrease, possibly concerned with that it is the one of the pro-inflammatory factors and the earliest and the most important endogenous transmitter in the inflammatory reaction.
5. When successive administration to the second day and the third day, rats'W/D and pathologic change of lung improved compared to the first day, which reveals that the effect of successive administration is better than administration only one time.
6. Compared with the normal does of Tanreqing, high does fails to benefit the ALI rats, instead, makes the incidence of adverse effect and the mortality of this group seem higher.
中医虽无“急性肺损伤”的病名,但按其临床表现,应属“喘证”、“结胸”“喘脱”、“暴喘”等病的范畴,病位主要在肺和肾。肺失宣降、气机逆乱、毒邪壅滞是发病早期的重要病机,其中的毒邪包括热、毒、痰、瘀等,患者热、毒、痰、喘、瘀、闭的表现突出,宜运用清热解毒、宣肺平喘、豁痰开窍、攻里通下等治法。综合既往研究结果提示,一些以清热解毒或清热化痰为指导原则的中药方剂或中成药经实验验证,对ALI有一定效果。
[目的]通过设立常规治疗、常规治疗加乌司他丁、常规治疗加清热化痰法等三组,对比三组疗效,评价清热化痰法对痰热蕴肺型ALI的临床疗效,并结合动物实验研究其可能的作用机制,另外还探讨痰热清注射液在治疗ALI方面是否存在量效关系及其安全性,为今后更深一步的研究打下基础。
[方法]临床研究采用随机、单盲研究方法。2010年2月至2012年2月期间,从广州中医药大学第一附属医院重症医学科,以及广州市中医医院急诊科、呼吸科纳入的符合标准的病人共计46例。将病人随机分入常规治疗组(A组)、常规治疗加乌司他丁组(B组)、常规治疗加中药组(C组)等三组,三组的治疗方案分别是常规治疗、常规治疗加乌司他丁、常规治疗加清热化痰法,疗程为14天。观察住院期间患者中、西医症候的变化,以及呼吸机使用时间、血清炎症因子、Murray肺损伤评分等指标。
本动物实验以静脉注射脂多糖的方法复制ALI大鼠模型。通过对正常对照组(A组)、急性肺损伤模型组(B组)、乌司他汀对照组(C组)、中药常规剂量组(D组)、中药高剂量组(E组)等各组大鼠分别予生理盐水5ml、生理盐水5ml、乌司他丁(2.1万U/Kg)、常规剂量痰热清(2.1ml/Kg)、高剂量痰热清(4.2ml/Kg),连续给药3天,对照观察各组大鼠的肺组织匀浆中的各项炎症指标、肺湿干重量比、肺病理改变,以及各组死亡率,观察清热化痰法对ALI是否存在治疗作用,并初步探讨其作用机制和安全性。
[结果]临床研究发现,A、B、C三组治疗后的心率、氧合指数、胸片、Murray肺损伤评分等各项指标都较治疗前有明显改善(P<0.05)。而B、C两组又较A组改善明显(P<0.05或P值接近0.05)。B、C两组之间未见明显的差异性(P>0.05)。A组治愈3例,好转5例,未愈3例,死亡3例,总有效率57.14%；B组治愈7例,好转5例,未愈2例,死亡2例,总有效率68.75%；C组治愈7例,好转6例,未愈2例,死亡1例,总有效率75%。但三组间资料比较未见有统计学意义的差异(P>0.05)。在呼吸机通气时间,以及TNF-α、IL-6、MMP-9等指标的比较上,B、C两组均较A组的数值明显降低(P<0.05)。而B、C两组之间则未见明显的差异性(P>0.05)。
动物实验方面,同日不同组之间的比较,C、D、E三组3天的IL-6、TNF-α、MMP-9等炎症指标,以及W/D、病理切片结果均较B组有显著性的改善(P<0.05)；而此三者之间未见明显差异(P>0.05)。同组不同日之间的比较,C3与C1的W/D比较有明显的下降,C2、D2组的TNF-α水平与C1、D1组比较有明显的下降(P<0.05),E3组与E1组的TNF-α水平也有明显的下降(P<0.05),而IL-6、MMP-9则无上述变化。而W/D、肺部切片等在连续给药3天中均有不同程度的逐日改善。不良事件方面,B组在第1天死亡1只,C组在第3天死亡1只,D组在第2天死亡1只,E组大鼠在第1、2、3天各死亡1只。B、C、D三组的死亡率均为5.6%,E组死亡率为16.7%。另外,E组大鼠有半数出现大便溏、次数多的不良反应。
[结论]1、常规治疗、常规治疗加用乌司他丁、常规治疗加用清热化痰法三种治疗方法,均对ALI有一定的治疗效果,体现在患者临床表现、影像学检查和实验室检查等方面的改善。而后二者又比常规治疗效果更佳,体现在后二者使用呼吸机的时间更短,血液中炎症因子含量下降更明显,但后二者之间未见有明显差异。清热化痰法治疗痰热蕴肺型ALI的机制之一是降低患者血清中TNF-α、IL-6、MMP-9等炎症因子的水平。清热化痰法能改善痰热蕴肺型ALI的病情,阻断其向更严重的ARDS发展,缩短呼吸机的使用时间,提高临床疗效。
2、从中医角度评价疗效,常规治疗加用清热化痰法对痰热蕴肺型ALI有一定的疗效,但与单纯西医常规治疗,以及常规治疗加用乌司他丁相比未有统计学意义上的差异,需进行更大样本量的临床观察以进一步研究。另外,在研究中我们发现,加用清热化痰法的病例大多大便偏软,甚偏溏,根据肺与大肠相表里的理论,通便既可降肺气,又可清肺热,因此这可能是清热化痰法治疗痰热蕴肺型ALI的机制之一。所以,可以在辨证使用清热化痰的治法基础上,酌加泻下通便的中药,可能会增加疗效。
3、乌司他丁、常规剂量痰热清、大剂量痰热清均对ALI大鼠有一定的治疗作用,三者的疗效相当,其作用机制是通过降低肺局部TNF-α、IL-6、MMP-9等炎症因子的水平以减轻肺部炎症反应,改善肺部病理改变,从而对ALI大鼠的肺部起到一定的保护作用。
4、与第1天相比,当用药到第2天或第3天时,乌司他丁、常规剂量痰热清、大剂量痰热清三组大鼠的肺匀浆中的TNF-α含量均有明显的下降。TNF-α呈逐日降低的趋势,可能与它是早期主要的前炎症因子之一,是炎性反应中释放最早、最重要的内源性介质有关。
5、连续给药到第2天、第3天, ALI大鼠的W/D和肺部病理切片均较第1天有一定改善,提示连续用药较单纯用药1次可获得更好的疗效。
6、与常规剂量相比,大剂量的痰热清并未能使ALI大鼠获得更好的疗效,反而令该组大鼠的不良反应发生率和死亡率有增高的趋势。
[Background] Acute lung injury (ALI), one of the respiratory system emergency cases, first reported by Ashbaugh in1967, is acute, progressive and hypoxia respiratory failure caused by multiple endo-or ecto-lung etiological factors. ALI has high morbidity and fatality, but its pathogenesis is not fully identified. At present, its genesis and development is regarded as the result of multiple etiological factors. among these, over-imbalance inflammatory reaction is regarded as one of the most important factors. Specific therapy is absent so far.
The name "Acute lung injury" was not exist in TCM, but according to clinical manifestation, ALI pertains to "panting patterns","chest bind","panting desertion" and "fulminant panting", of which position of disease is lung and kidney. The vital and pristine pathogenesis is impairment of dispersing and descending function of the lung, disorder of the activities of qi, and also obstruction of poison of lung. The poison factors include heat, toxin, phlegm and stasis, by which the patients'appearance with heat, toxin, phlegm panting, stasis and blocking is significant. To treat these, the method of treatment, including clearing heat and resolving toxin, diffusing the lung and calming panting, sweeping phlegm and opening the orifices, and precipitation, should be used. The results of previous researches revealed that some formula and Chinese pattern medicines directed by either the principle of clearing heat and resolving toxin or clearing heat and transforming phlegm have a certain extent of curative effect.
[Objective] To evaluate the curative effect for the phlegm-heat-obstructing-the-lung-type ALI of the management of clearing heat and transforming phlegm, we establish the groups of conventional therapy, conventional therapy adding ulinastatin (UTI) and conventional therapy adding clearing heat and transforming phlegm, and compare them. On the other side, we investigate the mechanism of the management of clearing heat and transforming phlegm according to the animal experiment. In additional, we investigate the dose-effect relationship and safety of Tanreqing injection curing ALI for further study.
[Method] We used randomized, single blind methods in clinical research. From February2010to February2012, we collected46patients from the First Affiliated Hospital of Guangzhou TCM University and Guangzhou hospital of TCM, who met the diagnosis criterion of ALI. We randomly divided them into the group of conventional therapy (group A), of conventional therapy adding UTI (group B) and of conventional therapy adding Chinese medicine (group C). The therapeutic regimens of these3groups respectively were conventional therapy, conventional therapy adding UTI and conventional therapy adding clearing heat and transforming phlegm, while their courses of treatment were14days. The patients'symptoms of Chinese medicine and Western medicine, the time of using breathing machine, inflammatory factors in serum and lung injury score (LIS) were observed in the duration of hospital stay.
The rat model of ALI was produced with intravenous injecting lipopolysaccharide. After establishing the group of normal control (group A), of ALI model (group B), of UTI (group C), of normal does of Chinese medicine (group D) and of high does of Chinese medicine (group E), we respectively gave them normal sodium5ml, normal sodium5ml, UTI (21, OOOU/kg), Tanreqing(2. lml/kg) and Tanreqing(4.2ml/kg), for3days consecutively, then compared inflammatory factors in the rats'lung homogenate, the wet weight-dry weight ratio(W/D), pathologic change of lung, and the mortality of each group.
[Result] The result of clinical study revealed that compared to pretherapy, three groups had significant changes in the aspects of breathing rate, heart rate, saturation of blood oxygen, oxygenation index, sternite and LIS after treatment (P<0.05). Generally speaking, the changes of group B and C were more significant then that of group A, while not obvious between group B and C. According to the viewpoint of Chinese medicine, in group A,3patients were cured,5improved,3not cured,3dead, and total effective rate of this group was57.14%; in group B,7patients were cured,5improved,2not cured,2dead, and total effective rate of this group was68.75%; in group C,7patients were cured,6improved,2not cured,1dead, and total effective rate of this group was75%. But no significant difference was observed. In the aspects of duration of ventilation with breathing machine and the inflammatory factors, such as TNF-α, IL-6and MMP-9, group B and C degraded more significantly than group A(P<0.05), while there was no difference between group B and group C(P>0.05).
The result of animal experiment revealed that in the aspect of horizontal comparison of the same day, the indexes, such as TNF-α, IL-6, MMP-9, W/D and pathologic change of lung, of group C, D and E were more significant than those of group B(P<0.05), while no significant difference among group C, D, E(P>0.05). On the other side, in the aspect of longitudinal comparison of the same group, the W/D of C3had more significant decrease than C1,whle significant decrease of TNF-α was present between C2and Cl, D2and D1, E3and El(P<0.05), but no such change of IL-6or MMP-9. During these3days, different extent of improve in W/D and pathologic change of lung was observed day by day. A rat of group B died in the first day, one of group C died in the third day, one of group D died in the second day, while a rat of group E died in everyday. The mortality of group B, C and D was5.6%, while group E was16.7%. Besides, half rats of group E appeared frequent and loose stool.
[Conclusion]1. Conventional therapy, conventional therapy adding UTI and conventional therapy adding the management of clearing heat and transforming phlegm are effective for ALI, reflected in the improve of the patients'clinical performance, imageology examination and laboratory examination. The latter two are better than conventional therapy, for the time of using breathing machine was shorter and inflammatory factors in serum were less, while they had no significant difference with each other. One of the mechanisms of the management of clearing heat and transforming phlegm curing the phlegm-heat-obstructing-the-lung-type ALI is decrease the content of TNF-α, IL-6, MMP-9in serum. It can improve the phlegm-heat-obstructing-the-lung-type ALI, arrest its growth to ARDS, shorten the time of using breathing machine and enhance curative effect.
2. According to the viewpoint of Chinese medicine, conventional therapy adding the management of clearing heat and transforming phlegm has some curative effect for the phlegm-heat-obstructing-the-lung-type ALI, but shows no significant difference with conventional therapy or conventional therapy adding UTI, thus the research of larger sample size is required. In additional, we find the patiens'stool of conventional therapy adding clearing heat and transforming phlegm is soft, or even sloppy. Basis on the theory of "lung and large intestine are exterior and interior", purgation helping downbear lung-qi and clear lung-heat, it is regarded as one of the mechanisms of the management of clearing heat and transforming phlegm. Therefore, it can enhance curative effect by adding the herb for relieving constipation by purgation on the base of the pattern identification and using he management of clearing heat and transforming phlegm.
3. UTI, normal does of Tanreqing and high does of Tanreqing has respectively some curative effect for ALI rats, which has no significant difference with each other. The mechanism is that the content of inflammatory factors such as TNF-a, IL-6and MMP-9in lung is decreased so that the inflammatory reaction is gentler, pathologic change of lung is improved and therefore lung is protected.
4. In the second day and the third day, the content of TNF-α in the rats'lung homogenate from the group of UTI, normal does of Tanreqing and high does of Tanreqing was lower than in the first day. TNF-α displays the trend of day-by-day decrease, possibly concerned with that it is the one of the pro-inflammatory factors and the earliest and the most important endogenous transmitter in the inflammatory reaction.
5. When successive administration to the second day and the third day, rats'W/D and pathologic change of lung improved compared to the first day, which reveals that the effect of successive administration is better than administration only one time.
6. Compared with the normal does of Tanreqing, high does fails to benefit the ALI rats, instead, makes the incidence of adverse effect and the mortality of this group seem higher.
引文
[1]张秋金,沈洪,张维,等纳洛酮与甲基泼尼松龙联用对急性肺损伤大鼠肺组织核转录因子-κB表达的影响[J].中国危重病急救医学,2005；17(6)：370-372
[2]中华医学会重症医学分会.急性肺损伤／急性呼吸窘迫综合征诊断和治疗指南(2006)[J].中国危重病急救医学,2006；18(12)：706-710
[3]Gordon R1Cetennial review acute respiratory distress syndrome a historical perspective [J]. Respir Crit CareMed,2005; 172:798-806
[4]Lu YM, Song ZF, Zhou X, et al. A 12-month clinical survey of incidence and outcome of acute respiratory syndrome in Shanghai intensive care unit [J]. Intensive CareMed,2004; 30(12):2197-2203
[5]Bernard GR, Artigas A, Brigham KL, et al1The American-European consensus conference on acute respiratory distress syndrome:definitions, mechanisms, relevant outcomes, and clinical trial coordination[J]. Am J Respir Crit CareMed,1994; 149(3):818-8241
[6]黎毅明,何国清.急性肺损伤和急性呼吸窘迫综合征发病机制研究进展[J].中国实用内科,2006；26(2)：243-245
[7]刘红菊,李元桂,毕爱华.肿瘤坏死因子在急性肺损伤发病机制中的作用[J].国外医学免疫分册,1996；(5)：229-231
[8]OKAJIMA K. Regulation of inflammatory responses by endothelial cells-understanding the molecular mechanism(s) and its therapeutic application to sepsis[J]. Masui,2008; 57(3):311-20
[9]BERHANE K, MARGANA R K, BOGGARAM V. Characterization of rabbit SP-B promoter region responsive to downregulation by tumornecrosis factor-alpha [J]. Am J Physiol Lung Cell Mol Physiol,2000; 279(5):L806-814.
[10]MIA KOTINA O L, SN YDER J M. TNF-alpha inhibits SP-A gene expression in lung epithelial cells via p38 MAPK[J]. Am J Physiol Lung Cell Mol Physiol, 2002; 283(2):L418-427
[11]WILCOX P, MILLIKEN C, BRESSL ER B. High-dose tumor necOFRis factor alpha produces an impairment of hamster diaphragm cont ractility. Attenuation with a pOFRtaglandin inhibitor[J]. Am J Respir Crit Care Med,1996; 153 (5):1611-1615.
[12]WILCOX P, OSBORNE S, BRESSL ER B. Monocyte inflammatory mediators impair in vitro hamster diaphragm cont ractility[J].Am Rev Respir Dis,1992; 146 (2):462-466
[13]Tilg H, Dinarello CA, Mier JW. IL-6 and APPs:anti-inflammatory and immunosuppressive mediators[J]. Immunol Today,1997; 18:428-432
[14]关岚,涂家红,李天水,等.白细胞介素在急性肺损伤大鼠中的作用[J].中国急救复苏与灾害医学杂志,2008；3(12)：728-730,733
[15]李兴旺,曾邦雄,徐涛,等.内毒素诱导急性肺损伤大鼠肺泡灌洗液明胶酶活性的变化[J].临床麻醉学杂志,2005；21(2)：113-115.
[16]Coimbra R, Melbostad H, LoomisW, et al. LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition:effects on proinflammatory mediators, metallop roteinases, NF-kappaB, and ICAM-1 expression[J]. J Trauma,2006; 60(1):115-125
[17]贺兼斌,杨凯,向志,等.NF-κ Bp65在实验性大鼠ALI肺组织中的表达及清开灵的干预研究[J].南华大学学报·医学版,2007；35(3)：359-364
[18]王建春,姜鹏,谢艳萍,等.急性肺损伤大鼠肺组织NF—κ B表达的研究[J].中国现代医学杂志,2006；16(16)：2448-2452
[19]罗真春,黄燕,秦开秀,等.核转录因子-κB在急性肺损伤小鼠中的动态表达[J].重庆医学,2009；38(16)：2005-2006
[20]Comellas AP, Briva Al Role of endothelin-1 in acute lung injury [J]. Transl Res,2009; 153 (6):263-271
[21]赵业婷,姚三巧,赵金垣.内皮素与急性呼吸窘迫综合征[J].中国职业医学,2005；32(6)：49-51
[22]Fagan KA, McMurtry IF, Rodman DM1 Role of endothelin-1 in lung disease [J]. Respir Res,2001; 2(2):90-101
[23]Wakayama F, Fukuda I, Suzuki Y, et al. Neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury after cardiopulmonary bypass in the rabbit endotoxemia model [J]. Ann Thorac Surg,2007; 83(1):153-160
[24]Kazuhito Kawabata, Tetsuya Hagio, ShigeruMatsumoto, et allDelayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters [J]. Am J Resp-ir Crit CareMed,2000,161(6):2013-2018
[25]岳茂兴.多器官功能障碍综合征现代救治[M].北京：清华大学出版社,2004：1
[26]MatthayMA, Zimmerman GA, Esmon C, et al. Future research directions in acute lung injury:summary of a National Heart, Lung, and Blood Institute working group [J]. Am J Resp ir Crit Care Med,2003; 167(7):1027-1035
[27]Sabharwal AK, Bajaj SP, Ameri A, et al. Tissue factor pathway inhibitor and von Willsbrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis [J]. Am J Respir Crit Care Med,1995; 151:758-767
[28]Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury--new therapeutic targets?[J]. Keio J Med,2005; 54(3):142-149
[29]Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement:role of sphingosine 1-phosphate receptor transactivation[J]. J Biol Chem,2005; 280(17):86-93
[30]Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome:a clinical review [J]. Lancet,2007; 369(9572):1553-1564
[31]Bernard GR, Ely EW, Wright TJ, Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis [J]. Crit Care Med, 2001; 29(11):2051-2059
[32]MatthayMA. Severe sep sis:a new treatment with both anticoagulant and anti-inflammatory properties [J]. N Engl J Med,2001; 344(10):759-762
[33]Nelson JL, DeMichele SJ, Pacht ER, et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants on antioxidant status in patient s with acute respiratory distress syndrome [J]. J PEN J Parenter Enteral Nutr,2003,27(2):98-104
[34]梅双,赵金垣,温韬,等.油酸性急性肺损伤启动机制的实验研究[J].中国工业医学杂志,2007；20(2)：67-78
[35]景友玲,王艳蕾,孙娜,等.氧化应激在化学性急性肺损伤中的作用[J].工业卫生与职业病,2010；36(3)：151-154
[36]邢海波,李刚,徐亚平,等.依达拉奉对脓毒症大鼠肺损伤的保护作用[J].中国呼吸与危重监护杂志,2009；8(2)：176-180
[37]Kear SR, Kelly CJ, Barry M, et al. Vitamin C reduces ischaemia-reperfus ion-induced acute lung injury [J]. Eur J Vasc Endovasc Surg,1999; 17(6):533-536
[38]Uchiyama K, Takano H, Yanagisawa R, et al. A novel water-soluble vitamin E derivative prevent's acute lung injury by bacterial endotoxin[J]. Clin Exp Pharmacol Physiol,2004; 31(4):226-230
[39]Tsuji C, Shioya S, Hirota Y, et al. Increased production of nitrotyrosine in lung tissue of rats with radiation-induced acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol,2000; 278:L719-L725
[40]Bernard GR, ArtigsA, Brigham KL, et al. The American-European Consensus Conference on ARDS:definitions, mechanisms, relevant outcomes, and clinical trial coordination[J]. Am J Respir Crit Care Med,1994; 148(3 Pt 1):818-824
[41]白春学.急性呼吸窘迫综合征诊治中存在的问题和对策[J].中外医疗,2008；5：18-20
[42]Esteban A, Fernandez Segoviano P, Frutos Vivar F, et all Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings[J]. Ann Intern Med,2004; 141 (6):440
[43]Ferguson ND, Frutos Vivar F, Esteban A, et all Acute respiratory distress syndrome:underrecognition by clinicians and diagnostic accuracy of three clinical definitions[J]. Crit Care Med,2005; 33(10):2228
[44]钱桂生.急性肺损伤和急性呼吸窘迫综合征的诊断与治疗[J].解放军医学杂志,2009；34(4)：371-373
[45]朱贵月,解健,李涛,等.乌司他丁对ARDS患者TNF-α、IL-1β、IL-6、IL-8的影H响[J].山东医药,2003；43(25)：27
[46]施旖旎,黄子通,蒋龙元,等.乌司他丁治疗全身炎症反应综合征的临床研究[J].中国急救医学,2004；24(10)：738-739.
[47]Nakanishi K, Takeda S, Sakamoto A, et al. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and ppulmonary dysfunction [J]. Crit Care Med,2006; 34:1-7
[48]徐康清,孙培吾,黄文起,等.乌司他丁对体外循环心脏手术后肺功能的影响[J].中华胸心血管外科杂志,2004；20：7-9
[49]吴兴茂,汪海源,李国福,等.乌司他丁对急性呼吸窘迫综合症(ARDS)患者的肺保护作用观察[J].南华大学学报·医学版,2006；34(2)：237-238
[50]陈海东,卓越.乌司他丁治疗急性肺损伤疗效观察[J].临床肺科杂志,2006;11(2)：252-253
[51]向镜芬,杨祥,龚剑锋.乌司他丁对ARDS/ALI患者呼吸力学和氧化应激的影响[J].山东医药,2011；51(5)：79-80
[52]李文放,陈杰.乌司他丁在急性呼吸窘迫综合征的临床应用研究[J].中国急救医学,2006；26(9)：644-646
[53]Su X, Wang L, Song Y, et al. Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide [J]. Intensive Care Med,2004; 30:133-140
[54]吴俊峰,段俊峰,张耀森,等.大剂量AMB对胸部创伤所致肺损伤的治疗作用[J].临床肺科杂志,2008；13(11)：1420.
[55]金钧,郭强,王俊,等.大剂量AMB对ARDS合并机械通气相关肺炎的作用研究 [J].临床肺科杂志,2008；13(6)：680—681.
[56]赵中江,孟新科,杨径.沐舒坦对急性肺损伤肺保护作用的研究[J].中国现代医学杂志,2004；14(22)：106-108
[57]张清.沐舒坦治疗ARDS的机制[J].国外医学麻醉学与复苏学分册,2003；24(3)：182-184
[58]钟耀区,利旭辉,吴思仿,等.大剂量沐舒坦治疗ARDS疗效观察[J].2010；23(8)：2614-2615
[59]赵双平,艾宇航,徐道妙.大剂量沐舒坦对急性呼吸窘迫综合征患者呼吸功能的影响[J].中华麻醉学杂志,2005；25(7)：543-544
[60]唐季生,向美丽.大剂量沐舒坦对急性呼吸窘迫综合征患者抗氧化能力的影响[J].实用全科医学,2007；11(5)：977-978
[61]李蜀,殷应勇.沐舒坦梯度剂量对改善肺损伤ARDS患者Pa02和PaO2/FiO的评估[J].中国医疗前沿,2008；3(10)：14-15
[62]李海东,王志成,刘国祥.氨溴索对内毒素诱导急性肺损伤大鼠肺组织表面活性物质相关蛋白A表达影响[J].西南军医,2006；8(1)：32-34
[63]杨丽,马兴龙,李春树.不同剂量的盐酸AMB对海水淹溺大鼠肺泡表面活性物质的影响[J].大连医科大学学报,2010；32(3)：251-253
[64]Taylor RW, Zimmerman JL, Delliager RP, et al. Low dose inhaled nitric oxide in patients with acute lung injury:a randomized controlled trial [J]. JAMA,2004; 291 (13):1603-1609
[65]付明生,肖晓辉,万毅新.吸人前列腺素E对脂多糖所致大鼠急性肺损伤模型Thl/Th2的影响[J].中国呼吸与危重监护杂志,2008；7(1)：47-51
[66]李冰冰,丁正年,王国军,等.肺泡表面活性物质灌洗对家兔急性盐酸肺损伤后血气及气道压力的治疗效果研究[J].南京医科大学学报(自然科学版),2004；242：171-174
[67]KrauseMF, WiemannT, ReisnerA, et al. Surfactant reduces extravascular lungwater and invasion of polymorphonuclear leukocyte into the lung in a pigletmodel of airway lavage [J]. Pulm Pharmacol Ther,2005; 18(2):129-139
[68]Mikawa K, Nishina K, Takao Y, et al. Intratracheal application recombinant surfactantprotein-C surfactant to rabbits attenuates acute lung injury induced by intratracheal acidified infant form [J]. Anesth Analg, 2004; 98 (5):1273-1279
[69]Jain D, Dodia C, Sandra R, et al. SP-A is necessary for increased clearance of alveolarDPPC with hyperventilation or secretagogues [J]. Am J Physiol Lung Cell Mol Physiol,2003; 284(15):759-765
[70]Wang H, Zhang ZH, Yan XW, et al. Amelioration of hemodynamics and oxygen metabolism by continuous venovenous hemofiltration in experimental porcine pancreatitis[J]. World J Gastroenterol,2005; 11 (1):127-131
[71]Jiang HL, XueWJ, Li DQ, et al. Influence of continuous veno-venous hemofiltration on the course of acute pancreatitis [J]. World JGastroenterol, 2005; 11(31):4815-4821
[72]Reyes YA, Shimoyama T, Akamat su H, et al. MCI-186(edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A (2) in an isolated rat lung model after 18 h of cold preservation[J]. Eur JCardiot horac Surg,2006,29 (3):304-311
[73]崔燕, 彭乱顺, 杨洪霞.依达拉奉对百草枯中毒患者肺损伤的防治作用[J].中国误诊学杂志,2008；8(15)：3599-3600
[74]梁韶军,刘曼玲,李志超,等.胰岛素对内毒素所致的急性肺损伤的防治作用[J].心脏杂志,2009；21(4)：475-479
[75]陈天琪.浅谈中医对急性肺损伤的认识[J].贵阳中医学院学报,2006；28(5)：7-8
[76]肖光华,吴敏,宓越群.急性肺损伤中医病机及治法探讨[J].上海中医药杂志,2008;42(10)：80-81
[77]金星、郑风杰.急性肺损伤中医学发病机制及治疗思路探讨[J].中医药临床杂志,2008;20(1)：76-77
[78]耿耘,卫敏.急性呼吸窘迫综合征的中医治疗概况[J].实用中西医结合临床,2003；3(2)：61
[79]丁慧芬.中医肺与急性肺损伤的发病关系初探[J].辽宁中医杂志,2004；31(10)：823-824
[80]张广梅,李福安,童丽.热痛方对大鼠急性肺损伤保护作用的实验研究[J].青海医学院学报,2006；27(2)：104-106.
[81]张杰,薛玉凤,赵聚宾.中药清毒液对急性肺损伤兔肺组织和血浆一氧化氮和内皮素水平的影响[J].时珍国医国药,2005；16(7)：607-608.
[82]李丽娜,王庆国.从气血水探讨急性肺损伤的中医病机[J].北京中医药大学学报,2008；31(5)：296-298
[83]王今达,高天元,崔乃杰,等.祖国医学“肺与大肠相表里”学说的临床意义及其本质的探讨[J].中西医结合杂志,1982；2(2)：77-81
[84]朱义用,景炳文,娄永华.大黄对肠源性感染早期肺损伤大鼠内毒素的影响[J].医药导报,2004,23(1)：13-15
[85]朱义用,景炳文,娄永华.大黄对肠源性感染致早期肺损伤防治作用的机制探 讨[J].中国中西医结合杂志,2004；11(1)：53-56
[86]赵立伟,王滨,韩杰.大黄对脑外伤继发急性肺损伤影响的实验研究[J].黑龙江医药科学,2001；24(6)：29-30
[87]尹刚, 王志强,黄美蓉.大黄和肉苁蓉提取物对感染性休克模型大鼠肺损伤的影响[J].山东中医杂志,2003；23(11)：691-693
[88]李新宇,景炳文, 陈德昌,等.大黄对大鼠肠缺血—再灌注所致肺损伤防治作用的实验研究[J].中国急救医学,2002；22(4)：190-192
[89]李新宇,景炳文, 陈德昌,等.大黄对大鼠肠缺血再灌注所致肺损伤过程中内源性NO的影响[J].中国急救医学,1999；19(8)：454-456
[90]黄海萍,刘翠华.丹参对大鼠急性肺损伤保护作用的实验探讨[J].中国现代医药杂志,2008；10(6)：83-84
[91]叶亮.丹参对大鼠急性肺损伤防治作用的实验研究[J].中国临床保健杂志,2007;10(3)：272-274
[92]夏燕亮,刘昕.丹参对大鼠脓毒症急性肺损伤发生TNF-α的影响及对肺的保护作用[J].中药药理与临床,2004；20(6)：14-17
[93]蔡子良,张莹,周首璋.丹参注射液对大鼠重症急性胰腺炎并发肺损伤的影响[J].重庆医学,2006；35(14)：1281-1282
[94]李敏,李锋,胡波.丹参对大鼠急性肺损伤的保护作用[J].中药材,2007；30(4)：442-444
[95]李敏,李锋,胡波.丹参对内毒素致急性肺损伤大鼠肺水通道蛋白-1的调节效应[J].中国中医药信息杂志,2007；14(3)：30-32
[96]邱海波,周韶霞,蒋雄斌,等.雷公藤多甙对小鼠急性肺损伤的防治作用[J].中国中西医结合急救杂志,2001；8(2)：109-112
[97]章卓,刘明华,万敬员,等.积雪草苷对LPS诱导急性肺损伤COX-2/PGE2影响研究[J].中成药,2008；30(12)：1838-1839
[98]黄翠萍,杨和平.黄芪对脂多糖诱导大鼠急性肺损伤p38MAPK表达的影响[J].咸宁学院学报(医学版),2008；22(5)：373-375
[99]屠燕捷,杨爱东,郭永洁,等.不同治法对内毒素致急性肺损伤小鼠肺组织细胞因子的影响[J].四川中医,2008；26(7)：6-8
[100]周晓红,黄新莉,翟佳,等.大承气汤对脂多糖所致老年大鼠急性肺损伤的作用[J].中国老年学杂志,2009；29(4)：785-788
[101]李玉梅,卫洪昌,汪东颖.大承气汤治疗大鼠内毒素性ARDS的疗效分析及免疫调节机制研究[J].中国病理生理杂志,2009；25(10)：2027-2032
[102]邓青南,周建龙,郭振辉.清气化痰汤对急性肺损伤小鼠水通道蛋白1表达的影响[J].中国中医急症,2011；20(1)：77-79
[103]魏凯峰,常加松,张梅勇,等.升降散对急性肺损伤大鼠肺细支气管粘膜上皮细胞ICAM-1表达的影响[J].江西中医学院院报,2007;19(3)：55-57
[104]曹慧玲, 吕士杰, 姜艳霞,等.急性肺损伤大鼠氧自由基变化及不同中药治疗作用的对比[J].中国中西医结合急救杂志,2006；13(3)：146-149
[105]郑丰杰,李宇航,王庆国,等.清热解毒药配伍桔梗汤对急性肺损伤大鼠肺核因子Kappa B p65蛋白表达的影响[J].中华中医药杂志,2008：23(7)：586-589
[106]王非,张长志,李晓娟,等.清瘟败毒饮对急性肺损伤小鼠促炎症和抗炎症因子的影响[J].浙江中医药大学学报,2011；35(3)：391-394
[107]王非,骆仙芳,赵玮,等.清瘟败毒饮影响急性肺损伤大鼠肺组织NK-κ Bp65表达的实验研究[J].中华中医药学刊,2011；29(6)：1290-1295
[108]何神地,骆仙芳,赵玮,等.清瘟败毒饮对内毒素性急性肺损伤大鼠血清细胞因子TNF-α、IL-8、IL-10表达的影响[J].中华中医药学刊,2011；29(9)：2067-2070
[109]闫龙,黄小民.痰热清注射液对急性肺损伤大鼠保护机制的实验研究[J].中国中医急症,2011;20(4)：587-589
[110]刘红菊,张玉,辛建保,等.痰热清的抗氧化作用及对急性肺损伤的抑制作用研究[J].中国医院药学杂志,2009；29(19)：1607-1610
[111]王香婷,魏民,方朝义,等.补气活血方药对衰老性ALI大鼠血清及肺组织中LDH含量的影响[J].中国中医基础医学杂志,2007；13(11)：833-834
[112]王香婷,朱晓红,魏民,等.补气活血方药对衰老性急性肺损伤大鼠SOD及MDA的影响[J].中国中医基础医学杂志,2009；16(6)：435-436
[113]方朝义,王香婷,刘惠聪,等.补气活血治疗对衰老性急性肺损伤大鼠MPO含量的影响[J].解放军医学杂志,2008；33,(4)：479-480
[114]王香婷,杨丽芸,朱晓红,等.补气活血方药对衰老性急性肺损伤大鼠IL-1β含量的影响[J].中国老年学杂志,2009；29(8)：1928-1929
[115]方朝义,王香婷,魏民,等.补气活血方药对衰老急性肺损伤大鼠模型血液及肺组织中ET21和NO含量的影响[J].中国老年学杂志,2007；21(11)：2167-2169
[116]张之龄,沈琪琦,朱健,等.血必净对脂多糖诱导的急性肺损伤大鼠肺组织纤溶酶原激活物抑制剂21表达的影响[J].中国临床保健杂志,2011；14(2)：163-166
[117]张远新,黄伟青,谢玉宝.参麦对内毒素型急性肺损伤家兔血TNF-α、IL-6变化的研究[J].国际医药卫生导报,2009；15(22)：13-16
[118]黄翠萍,杨和平,张珍祥.参麦注射液对脂多糖诱导大鼠急性肺损伤防护机制探讨[J].中华结核和呼吸杂志,2005；：28(1)：67-67
[119]曹慧玲,王新成,姜艳霞,等.参脉对大鼠急性肺损伤时CRP水平的影响[J].中国实用医药,2007；2(4)：3-5
[120]韩宁,张永.参麦注射液对脑缺血再灌注后肺损伤大鼠血浆ET-1的影响[J]. 中华中医药学刊,2009；27(2)：314-316
[121]谢玉宝,黄伟青,梁子敬.参麦注射液对大鼠急性肺损伤的实验研究[J].中国现代医药杂志,2008；10(3)：16-18
[122]傅晓青,杨勇.益气补肺方对肺损伤大鼠TNF2α和肺组织的影响[J].浙江中西医结合杂志,2007；17(12)：753-755
[123]杨勇,傅晓青,董礼文,等.益气补肺方对急性肺损伤大鼠ET-1和MIF水平的影响[J].浙江临床医学,2008；10(4)：437-438
[124]杨爱东,汪东颖,李文雯,等.护津方对急性肺损伤大鼠肺组织金属基质蛋白酶2mRNA及其抑制因子2mRNA表达的影响[J].中国中医药科技,2010；17(2)：98-99
[125]许玲,吕书勤.益气泻热逐水化瘀中药对呼吸窘迫综合征大鼠影响的实验研究[J].中国中医急症,2009；18(4)：583-586
[126]陈健,许玲,吕书勤.益气通腑利水中药对ARDS大鼠肿瘤坏死因子-α和白细胞介素-10影响的实验研究[J].时珍国医国药,2011；22(4)：1009-1010
[127]王晓红,李义慧,杨俊泉,等.痰热清注射液对基质金属蛋白酶9的影响及防治放射性肺损伤的疗效观察[J].中国煤炭工业医学杂志,2009；12(1)：10-12
[128]王晓红,李义慧,杨俊泉,等.痰热清注射液对血浆内皮素-1的影响及防治放射性肺损伤的疗效观察[J].中国煤炭工业医学杂志,2008；11(12)：1823-1825
[129]陈菲菲,林丽娜,缪剑霞,等.参麦注射液对体外循环后肺损伤保护作用的临床研究[J].中国中西医结合杂志,2009；29(5)：414-417
[130]张锐,赵海蓉,崔鹏,等.痰热清注射液治疗严重脓毒症的临床观察[J].医药论坛杂志,2010；31,(13)：147-148
[131]徐志威.痰热清注射液治疗全身炎症反应综合征43例疗效观察[J].中国现代药物应用,2010；4(11)：116-117
[132]王波涌,张宗林,郭鹏程.痰热清注射液对急性胰腺炎肺损伤的疗效观察[J].中国药师,2006；9(3)：225
[133]黄登鹏,彭卫平,陈少武,等.痰热清注射液治疗重症急性胰腺炎抗炎作用观察[J].中国中医急症,200514(2)：117
[134]黄登鹏,彭卫平.痰热清注射液对多器官功能障碍综合症患者细胞因子表达的影响[J].中国中医急症,200615(4)：347
[135]吴伟胜,林宏.中药灌肠结合西药治疗急性呼吸窘迫综合征50例疗效观察[J].新中医,2004；34(5)：20-21
[136]梁战海.血必净注射液治疗创伤所致急性肺损伤效果观察[J].实用心脑肺血管杂志,2012；20(1)：111-112
[137]陈齐红,郑瑞强,林华,等.血必净注射液对急性呼吸窘迫综合征患者预后影响的前瞻性随机对照临床研究[J].中国危重病急救医学,2009；21(7)：405-408
[138]谢玉宝,梁子敬,黄伟青.急性肺损伤的中医药治疗进展[J].实用临床医药杂志,2008；12(2)：113-115
[139]李建生.中医药治疗急性肺损伤的研究进展[J].中国中西医结合急救杂志,1999;6(11)：523-524
[140]卢军锋,顾勤,刘宁.中医药在急性呼吸窘迫综合征诊疗中的应用[J].吉林中医药,2008；28(4)：243-245
[141]屠燕捷,郭永洁,杨爱东.中医不同治法治疗内毒素致急性肺损伤的实验研究进展[J].陕西中医,2008；29(4)：508-509
[142]田德禄.中医内科学[M].北京：人民卫生出版社.2002：78
[143]曹书华,王今达,李银平.从“菌毒并治”到“四证四法”——关于中西医结合治疗多器官功能障碍综合征辨证思路的深入与完善[J].中国危重病急救医学,2005;17(11)：641-643
[144]苏景深,刘恩顺,孙增涛.不同治法对ALI/ARDS大鼠炎性相关因子作用的影响[J].时珍国医国药,2011;22(3)：736-738
[145]刘恩顺,苏景深,孙增涛,等.通腑泻肺法对ALI/ARDS大鼠免疫炎症损伤影响的实验研究[J].天津中医药,2011；28(2)97-99
[146]谢晓华,杨银芬,张晓清,等.通腑泻热方对胸科急性肺损伤患者细胞因子的影响[J].广州中医药大学学报,2008；25(4)：294-296
[147]Wilmore D W, Smith R J,O'Dwyer S T, et al. The gut:a central organ after surgical stress [J]. Surgery,1988; 104(5):917-923
[148]李志军,李银平.肺与大肠相表里学说与多器官功能障碍综合征[J]. 中国中西医结合急救杂志,2004；11(3)：131-132
[149]万霞,刘建平.临床试验中的随机分组方法[J].中医杂志,2007；48(3)：216-219.
[150]倪宗瓒,曹素华,骆福添,等.卫生统计学[M].北京：人民卫生出版社,2004,第4版：267
[151]李琦,钱桂生,张青,等.不同剂量脂多糖对大鼠急性肺损伤效应的观察[J].第三军医大学学报,2004；26(10)：871-873
[152]黄继汉,黄晓晖,陈志扬,等.药理试验中动物间和动物与人体间的等效剂量换算[J].中国临床药理学与治疗学,2004；9(9)：1069-1072
[153]李澎涛,张娜,朱晓磊,等.痰热清注射液抗内毒素所致急性肺损伤的实验研究[J].中国药学杂志,2005；40(7)：518-521
[154]韦炳华,陈清.痰热清注射液的不良反应分析[J].中国医药导报,2011；8(1)：134-135
[155]李彬,李淑君.TNF—α和NF—κB在急性肺损伤中的作用机制[J].包头医学 院学报,2011；27(2)：120-121
[156]邢海波,李刚,徐亚平,等.内毒素性急性肺损伤大鼠肺组织中氧化指标的变化[J].实用医学杂志,2009；25(12)：1934-1936
[157]樊毫军,刘书盈,张健鹏,等.静脉注射内毒素致大鼠急性肺损伤模型的病理生理学指标评价[J].中国危重病急救医学,2006；18(8)：485-487
[2]中华医学会重症医学分会.急性肺损伤／急性呼吸窘迫综合征诊断和治疗指南(2006)[J].中国危重病急救医学,2006；18(12)：706-710
[3]Gordon R1Cetennial review acute respiratory distress syndrome a historical perspective [J]. Respir Crit CareMed,2005; 172:798-806
[4]Lu YM, Song ZF, Zhou X, et al. A 12-month clinical survey of incidence and outcome of acute respiratory syndrome in Shanghai intensive care unit [J]. Intensive CareMed,2004; 30(12):2197-2203
[5]Bernard GR, Artigas A, Brigham KL, et al1The American-European consensus conference on acute respiratory distress syndrome:definitions, mechanisms, relevant outcomes, and clinical trial coordination[J]. Am J Respir Crit CareMed,1994; 149(3):818-8241
[6]黎毅明,何国清.急性肺损伤和急性呼吸窘迫综合征发病机制研究进展[J].中国实用内科,2006；26(2)：243-245
[7]刘红菊,李元桂,毕爱华.肿瘤坏死因子在急性肺损伤发病机制中的作用[J].国外医学免疫分册,1996；(5)：229-231
[8]OKAJIMA K. Regulation of inflammatory responses by endothelial cells-understanding the molecular mechanism(s) and its therapeutic application to sepsis[J]. Masui,2008; 57(3):311-20
[9]BERHANE K, MARGANA R K, BOGGARAM V. Characterization of rabbit SP-B promoter region responsive to downregulation by tumornecrosis factor-alpha [J]. Am J Physiol Lung Cell Mol Physiol,2000; 279(5):L806-814.
[10]MIA KOTINA O L, SN YDER J M. TNF-alpha inhibits SP-A gene expression in lung epithelial cells via p38 MAPK[J]. Am J Physiol Lung Cell Mol Physiol, 2002; 283(2):L418-427
[11]WILCOX P, MILLIKEN C, BRESSL ER B. High-dose tumor necOFRis factor alpha produces an impairment of hamster diaphragm cont ractility. Attenuation with a pOFRtaglandin inhibitor[J]. Am J Respir Crit Care Med,1996; 153 (5):1611-1615.
[12]WILCOX P, OSBORNE S, BRESSL ER B. Monocyte inflammatory mediators impair in vitro hamster diaphragm cont ractility[J].Am Rev Respir Dis,1992; 146 (2):462-466
[13]Tilg H, Dinarello CA, Mier JW. IL-6 and APPs:anti-inflammatory and immunosuppressive mediators[J]. Immunol Today,1997; 18:428-432
[14]关岚,涂家红,李天水,等.白细胞介素在急性肺损伤大鼠中的作用[J].中国急救复苏与灾害医学杂志,2008；3(12)：728-730,733
[15]李兴旺,曾邦雄,徐涛,等.内毒素诱导急性肺损伤大鼠肺泡灌洗液明胶酶活性的变化[J].临床麻醉学杂志,2005；21(2)：113-115.
[16]Coimbra R, Melbostad H, LoomisW, et al. LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition:effects on proinflammatory mediators, metallop roteinases, NF-kappaB, and ICAM-1 expression[J]. J Trauma,2006; 60(1):115-125
[17]贺兼斌,杨凯,向志,等.NF-κ Bp65在实验性大鼠ALI肺组织中的表达及清开灵的干预研究[J].南华大学学报·医学版,2007；35(3)：359-364
[18]王建春,姜鹏,谢艳萍,等.急性肺损伤大鼠肺组织NF—κ B表达的研究[J].中国现代医学杂志,2006；16(16)：2448-2452
[19]罗真春,黄燕,秦开秀,等.核转录因子-κB在急性肺损伤小鼠中的动态表达[J].重庆医学,2009；38(16)：2005-2006
[20]Comellas AP, Briva Al Role of endothelin-1 in acute lung injury [J]. Transl Res,2009; 153 (6):263-271
[21]赵业婷,姚三巧,赵金垣.内皮素与急性呼吸窘迫综合征[J].中国职业医学,2005；32(6)：49-51
[22]Fagan KA, McMurtry IF, Rodman DM1 Role of endothelin-1 in lung disease [J]. Respir Res,2001; 2(2):90-101
[23]Wakayama F, Fukuda I, Suzuki Y, et al. Neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury after cardiopulmonary bypass in the rabbit endotoxemia model [J]. Ann Thorac Surg,2007; 83(1):153-160
[24]Kazuhito Kawabata, Tetsuya Hagio, ShigeruMatsumoto, et allDelayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters [J]. Am J Resp-ir Crit CareMed,2000,161(6):2013-2018
[25]岳茂兴.多器官功能障碍综合征现代救治[M].北京：清华大学出版社,2004：1
[26]MatthayMA, Zimmerman GA, Esmon C, et al. Future research directions in acute lung injury:summary of a National Heart, Lung, and Blood Institute working group [J]. Am J Resp ir Crit Care Med,2003; 167(7):1027-1035
[27]Sabharwal AK, Bajaj SP, Ameri A, et al. Tissue factor pathway inhibitor and von Willsbrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis [J]. Am J Respir Crit Care Med,1995; 151:758-767
[28]Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury--new therapeutic targets?[J]. Keio J Med,2005; 54(3):142-149
[29]Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement:role of sphingosine 1-phosphate receptor transactivation[J]. J Biol Chem,2005; 280(17):86-93
[30]Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome:a clinical review [J]. Lancet,2007; 369(9572):1553-1564
[31]Bernard GR, Ely EW, Wright TJ, Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis [J]. Crit Care Med, 2001; 29(11):2051-2059
[32]MatthayMA. Severe sep sis:a new treatment with both anticoagulant and anti-inflammatory properties [J]. N Engl J Med,2001; 344(10):759-762
[33]Nelson JL, DeMichele SJ, Pacht ER, et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants on antioxidant status in patient s with acute respiratory distress syndrome [J]. J PEN J Parenter Enteral Nutr,2003,27(2):98-104
[34]梅双,赵金垣,温韬,等.油酸性急性肺损伤启动机制的实验研究[J].中国工业医学杂志,2007；20(2)：67-78
[35]景友玲,王艳蕾,孙娜,等.氧化应激在化学性急性肺损伤中的作用[J].工业卫生与职业病,2010；36(3)：151-154
[36]邢海波,李刚,徐亚平,等.依达拉奉对脓毒症大鼠肺损伤的保护作用[J].中国呼吸与危重监护杂志,2009；8(2)：176-180
[37]Kear SR, Kelly CJ, Barry M, et al. Vitamin C reduces ischaemia-reperfus ion-induced acute lung injury [J]. Eur J Vasc Endovasc Surg,1999; 17(6):533-536
[38]Uchiyama K, Takano H, Yanagisawa R, et al. A novel water-soluble vitamin E derivative prevent's acute lung injury by bacterial endotoxin[J]. Clin Exp Pharmacol Physiol,2004; 31(4):226-230
[39]Tsuji C, Shioya S, Hirota Y, et al. Increased production of nitrotyrosine in lung tissue of rats with radiation-induced acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol,2000; 278:L719-L725
[40]Bernard GR, ArtigsA, Brigham KL, et al. The American-European Consensus Conference on ARDS:definitions, mechanisms, relevant outcomes, and clinical trial coordination[J]. Am J Respir Crit Care Med,1994; 148(3 Pt 1):818-824
[41]白春学.急性呼吸窘迫综合征诊治中存在的问题和对策[J].中外医疗,2008；5：18-20
[42]Esteban A, Fernandez Segoviano P, Frutos Vivar F, et all Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings[J]. Ann Intern Med,2004; 141 (6):440
[43]Ferguson ND, Frutos Vivar F, Esteban A, et all Acute respiratory distress syndrome:underrecognition by clinicians and diagnostic accuracy of three clinical definitions[J]. Crit Care Med,2005; 33(10):2228
[44]钱桂生.急性肺损伤和急性呼吸窘迫综合征的诊断与治疗[J].解放军医学杂志,2009；34(4)：371-373
[45]朱贵月,解健,李涛,等.乌司他丁对ARDS患者TNF-α、IL-1β、IL-6、IL-8的影H响[J].山东医药,2003；43(25)：27
[46]施旖旎,黄子通,蒋龙元,等.乌司他丁治疗全身炎症反应综合征的临床研究[J].中国急救医学,2004；24(10)：738-739.
[47]Nakanishi K, Takeda S, Sakamoto A, et al. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and ppulmonary dysfunction [J]. Crit Care Med,2006; 34:1-7
[48]徐康清,孙培吾,黄文起,等.乌司他丁对体外循环心脏手术后肺功能的影响[J].中华胸心血管外科杂志,2004；20：7-9
[49]吴兴茂,汪海源,李国福,等.乌司他丁对急性呼吸窘迫综合症(ARDS)患者的肺保护作用观察[J].南华大学学报·医学版,2006；34(2)：237-238
[50]陈海东,卓越.乌司他丁治疗急性肺损伤疗效观察[J].临床肺科杂志,2006;11(2)：252-253
[51]向镜芬,杨祥,龚剑锋.乌司他丁对ARDS/ALI患者呼吸力学和氧化应激的影响[J].山东医药,2011；51(5)：79-80
[52]李文放,陈杰.乌司他丁在急性呼吸窘迫综合征的临床应用研究[J].中国急救医学,2006；26(9)：644-646
[53]Su X, Wang L, Song Y, et al. Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide [J]. Intensive Care Med,2004; 30:133-140
[54]吴俊峰,段俊峰,张耀森,等.大剂量AMB对胸部创伤所致肺损伤的治疗作用[J].临床肺科杂志,2008；13(11)：1420.
[55]金钧,郭强,王俊,等.大剂量AMB对ARDS合并机械通气相关肺炎的作用研究 [J].临床肺科杂志,2008；13(6)：680—681.
[56]赵中江,孟新科,杨径.沐舒坦对急性肺损伤肺保护作用的研究[J].中国现代医学杂志,2004；14(22)：106-108
[57]张清.沐舒坦治疗ARDS的机制[J].国外医学麻醉学与复苏学分册,2003；24(3)：182-184
[58]钟耀区,利旭辉,吴思仿,等.大剂量沐舒坦治疗ARDS疗效观察[J].2010；23(8)：2614-2615
[59]赵双平,艾宇航,徐道妙.大剂量沐舒坦对急性呼吸窘迫综合征患者呼吸功能的影响[J].中华麻醉学杂志,2005；25(7)：543-544
[60]唐季生,向美丽.大剂量沐舒坦对急性呼吸窘迫综合征患者抗氧化能力的影响[J].实用全科医学,2007；11(5)：977-978
[61]李蜀,殷应勇.沐舒坦梯度剂量对改善肺损伤ARDS患者Pa02和PaO2/FiO的评估[J].中国医疗前沿,2008；3(10)：14-15
[62]李海东,王志成,刘国祥.氨溴索对内毒素诱导急性肺损伤大鼠肺组织表面活性物质相关蛋白A表达影响[J].西南军医,2006；8(1)：32-34
[63]杨丽,马兴龙,李春树.不同剂量的盐酸AMB对海水淹溺大鼠肺泡表面活性物质的影响[J].大连医科大学学报,2010；32(3)：251-253
[64]Taylor RW, Zimmerman JL, Delliager RP, et al. Low dose inhaled nitric oxide in patients with acute lung injury:a randomized controlled trial [J]. JAMA,2004; 291 (13):1603-1609
[65]付明生,肖晓辉,万毅新.吸人前列腺素E对脂多糖所致大鼠急性肺损伤模型Thl/Th2的影响[J].中国呼吸与危重监护杂志,2008；7(1)：47-51
[66]李冰冰,丁正年,王国军,等.肺泡表面活性物质灌洗对家兔急性盐酸肺损伤后血气及气道压力的治疗效果研究[J].南京医科大学学报(自然科学版),2004；242：171-174
[67]KrauseMF, WiemannT, ReisnerA, et al. Surfactant reduces extravascular lungwater and invasion of polymorphonuclear leukocyte into the lung in a pigletmodel of airway lavage [J]. Pulm Pharmacol Ther,2005; 18(2):129-139
[68]Mikawa K, Nishina K, Takao Y, et al. Intratracheal application recombinant surfactantprotein-C surfactant to rabbits attenuates acute lung injury induced by intratracheal acidified infant form [J]. Anesth Analg, 2004; 98 (5):1273-1279
[69]Jain D, Dodia C, Sandra R, et al. SP-A is necessary for increased clearance of alveolarDPPC with hyperventilation or secretagogues [J]. Am J Physiol Lung Cell Mol Physiol,2003; 284(15):759-765
[70]Wang H, Zhang ZH, Yan XW, et al. Amelioration of hemodynamics and oxygen metabolism by continuous venovenous hemofiltration in experimental porcine pancreatitis[J]. World J Gastroenterol,2005; 11 (1):127-131
[71]Jiang HL, XueWJ, Li DQ, et al. Influence of continuous veno-venous hemofiltration on the course of acute pancreatitis [J]. World JGastroenterol, 2005; 11(31):4815-4821
[72]Reyes YA, Shimoyama T, Akamat su H, et al. MCI-186(edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A (2) in an isolated rat lung model after 18 h of cold preservation[J]. Eur JCardiot horac Surg,2006,29 (3):304-311
[73]崔燕, 彭乱顺, 杨洪霞.依达拉奉对百草枯中毒患者肺损伤的防治作用[J].中国误诊学杂志,2008；8(15)：3599-3600
[74]梁韶军,刘曼玲,李志超,等.胰岛素对内毒素所致的急性肺损伤的防治作用[J].心脏杂志,2009；21(4)：475-479
[75]陈天琪.浅谈中医对急性肺损伤的认识[J].贵阳中医学院学报,2006；28(5)：7-8
[76]肖光华,吴敏,宓越群.急性肺损伤中医病机及治法探讨[J].上海中医药杂志,2008;42(10)：80-81
[77]金星、郑风杰.急性肺损伤中医学发病机制及治疗思路探讨[J].中医药临床杂志,2008;20(1)：76-77
[78]耿耘,卫敏.急性呼吸窘迫综合征的中医治疗概况[J].实用中西医结合临床,2003；3(2)：61
[79]丁慧芬.中医肺与急性肺损伤的发病关系初探[J].辽宁中医杂志,2004；31(10)：823-824
[80]张广梅,李福安,童丽.热痛方对大鼠急性肺损伤保护作用的实验研究[J].青海医学院学报,2006；27(2)：104-106.
[81]张杰,薛玉凤,赵聚宾.中药清毒液对急性肺损伤兔肺组织和血浆一氧化氮和内皮素水平的影响[J].时珍国医国药,2005；16(7)：607-608.
[82]李丽娜,王庆国.从气血水探讨急性肺损伤的中医病机[J].北京中医药大学学报,2008；31(5)：296-298
[83]王今达,高天元,崔乃杰,等.祖国医学“肺与大肠相表里”学说的临床意义及其本质的探讨[J].中西医结合杂志,1982；2(2)：77-81
[84]朱义用,景炳文,娄永华.大黄对肠源性感染早期肺损伤大鼠内毒素的影响[J].医药导报,2004,23(1)：13-15
[85]朱义用,景炳文,娄永华.大黄对肠源性感染致早期肺损伤防治作用的机制探 讨[J].中国中西医结合杂志,2004；11(1)：53-56
[86]赵立伟,王滨,韩杰.大黄对脑外伤继发急性肺损伤影响的实验研究[J].黑龙江医药科学,2001；24(6)：29-30
[87]尹刚, 王志强,黄美蓉.大黄和肉苁蓉提取物对感染性休克模型大鼠肺损伤的影响[J].山东中医杂志,2003；23(11)：691-693
[88]李新宇,景炳文, 陈德昌,等.大黄对大鼠肠缺血—再灌注所致肺损伤防治作用的实验研究[J].中国急救医学,2002；22(4)：190-192
[89]李新宇,景炳文, 陈德昌,等.大黄对大鼠肠缺血再灌注所致肺损伤过程中内源性NO的影响[J].中国急救医学,1999；19(8)：454-456
[90]黄海萍,刘翠华.丹参对大鼠急性肺损伤保护作用的实验探讨[J].中国现代医药杂志,2008；10(6)：83-84
[91]叶亮.丹参对大鼠急性肺损伤防治作用的实验研究[J].中国临床保健杂志,2007;10(3)：272-274
[92]夏燕亮,刘昕.丹参对大鼠脓毒症急性肺损伤发生TNF-α的影响及对肺的保护作用[J].中药药理与临床,2004；20(6)：14-17
[93]蔡子良,张莹,周首璋.丹参注射液对大鼠重症急性胰腺炎并发肺损伤的影响[J].重庆医学,2006；35(14)：1281-1282
[94]李敏,李锋,胡波.丹参对大鼠急性肺损伤的保护作用[J].中药材,2007；30(4)：442-444
[95]李敏,李锋,胡波.丹参对内毒素致急性肺损伤大鼠肺水通道蛋白-1的调节效应[J].中国中医药信息杂志,2007；14(3)：30-32
[96]邱海波,周韶霞,蒋雄斌,等.雷公藤多甙对小鼠急性肺损伤的防治作用[J].中国中西医结合急救杂志,2001；8(2)：109-112
[97]章卓,刘明华,万敬员,等.积雪草苷对LPS诱导急性肺损伤COX-2/PGE2影响研究[J].中成药,2008；30(12)：1838-1839
[98]黄翠萍,杨和平.黄芪对脂多糖诱导大鼠急性肺损伤p38MAPK表达的影响[J].咸宁学院学报(医学版),2008；22(5)：373-375
[99]屠燕捷,杨爱东,郭永洁,等.不同治法对内毒素致急性肺损伤小鼠肺组织细胞因子的影响[J].四川中医,2008；26(7)：6-8
[100]周晓红,黄新莉,翟佳,等.大承气汤对脂多糖所致老年大鼠急性肺损伤的作用[J].中国老年学杂志,2009；29(4)：785-788
[101]李玉梅,卫洪昌,汪东颖.大承气汤治疗大鼠内毒素性ARDS的疗效分析及免疫调节机制研究[J].中国病理生理杂志,2009；25(10)：2027-2032
[102]邓青南,周建龙,郭振辉.清气化痰汤对急性肺损伤小鼠水通道蛋白1表达的影响[J].中国中医急症,2011；20(1)：77-79
[103]魏凯峰,常加松,张梅勇,等.升降散对急性肺损伤大鼠肺细支气管粘膜上皮细胞ICAM-1表达的影响[J].江西中医学院院报,2007;19(3)：55-57
[104]曹慧玲, 吕士杰, 姜艳霞,等.急性肺损伤大鼠氧自由基变化及不同中药治疗作用的对比[J].中国中西医结合急救杂志,2006；13(3)：146-149
[105]郑丰杰,李宇航,王庆国,等.清热解毒药配伍桔梗汤对急性肺损伤大鼠肺核因子Kappa B p65蛋白表达的影响[J].中华中医药杂志,2008：23(7)：586-589
[106]王非,张长志,李晓娟,等.清瘟败毒饮对急性肺损伤小鼠促炎症和抗炎症因子的影响[J].浙江中医药大学学报,2011；35(3)：391-394
[107]王非,骆仙芳,赵玮,等.清瘟败毒饮影响急性肺损伤大鼠肺组织NK-κ Bp65表达的实验研究[J].中华中医药学刊,2011；29(6)：1290-1295
[108]何神地,骆仙芳,赵玮,等.清瘟败毒饮对内毒素性急性肺损伤大鼠血清细胞因子TNF-α、IL-8、IL-10表达的影响[J].中华中医药学刊,2011；29(9)：2067-2070
[109]闫龙,黄小民.痰热清注射液对急性肺损伤大鼠保护机制的实验研究[J].中国中医急症,2011;20(4)：587-589
[110]刘红菊,张玉,辛建保,等.痰热清的抗氧化作用及对急性肺损伤的抑制作用研究[J].中国医院药学杂志,2009；29(19)：1607-1610
[111]王香婷,魏民,方朝义,等.补气活血方药对衰老性ALI大鼠血清及肺组织中LDH含量的影响[J].中国中医基础医学杂志,2007；13(11)：833-834
[112]王香婷,朱晓红,魏民,等.补气活血方药对衰老性急性肺损伤大鼠SOD及MDA的影响[J].中国中医基础医学杂志,2009；16(6)：435-436
[113]方朝义,王香婷,刘惠聪,等.补气活血治疗对衰老性急性肺损伤大鼠MPO含量的影响[J].解放军医学杂志,2008；33,(4)：479-480
[114]王香婷,杨丽芸,朱晓红,等.补气活血方药对衰老性急性肺损伤大鼠IL-1β含量的影响[J].中国老年学杂志,2009；29(8)：1928-1929
[115]方朝义,王香婷,魏民,等.补气活血方药对衰老急性肺损伤大鼠模型血液及肺组织中ET21和NO含量的影响[J].中国老年学杂志,2007；21(11)：2167-2169
[116]张之龄,沈琪琦,朱健,等.血必净对脂多糖诱导的急性肺损伤大鼠肺组织纤溶酶原激活物抑制剂21表达的影响[J].中国临床保健杂志,2011；14(2)：163-166
[117]张远新,黄伟青,谢玉宝.参麦对内毒素型急性肺损伤家兔血TNF-α、IL-6变化的研究[J].国际医药卫生导报,2009；15(22)：13-16
[118]黄翠萍,杨和平,张珍祥.参麦注射液对脂多糖诱导大鼠急性肺损伤防护机制探讨[J].中华结核和呼吸杂志,2005；：28(1)：67-67
[119]曹慧玲,王新成,姜艳霞,等.参脉对大鼠急性肺损伤时CRP水平的影响[J].中国实用医药,2007；2(4)：3-5
[120]韩宁,张永.参麦注射液对脑缺血再灌注后肺损伤大鼠血浆ET-1的影响[J]. 中华中医药学刊,2009；27(2)：314-316
[121]谢玉宝,黄伟青,梁子敬.参麦注射液对大鼠急性肺损伤的实验研究[J].中国现代医药杂志,2008；10(3)：16-18
[122]傅晓青,杨勇.益气补肺方对肺损伤大鼠TNF2α和肺组织的影响[J].浙江中西医结合杂志,2007；17(12)：753-755
[123]杨勇,傅晓青,董礼文,等.益气补肺方对急性肺损伤大鼠ET-1和MIF水平的影响[J].浙江临床医学,2008；10(4)：437-438
[124]杨爱东,汪东颖,李文雯,等.护津方对急性肺损伤大鼠肺组织金属基质蛋白酶2mRNA及其抑制因子2mRNA表达的影响[J].中国中医药科技,2010；17(2)：98-99
[125]许玲,吕书勤.益气泻热逐水化瘀中药对呼吸窘迫综合征大鼠影响的实验研究[J].中国中医急症,2009；18(4)：583-586
[126]陈健,许玲,吕书勤.益气通腑利水中药对ARDS大鼠肿瘤坏死因子-α和白细胞介素-10影响的实验研究[J].时珍国医国药,2011；22(4)：1009-1010
[127]王晓红,李义慧,杨俊泉,等.痰热清注射液对基质金属蛋白酶9的影响及防治放射性肺损伤的疗效观察[J].中国煤炭工业医学杂志,2009；12(1)：10-12
[128]王晓红,李义慧,杨俊泉,等.痰热清注射液对血浆内皮素-1的影响及防治放射性肺损伤的疗效观察[J].中国煤炭工业医学杂志,2008；11(12)：1823-1825
[129]陈菲菲,林丽娜,缪剑霞,等.参麦注射液对体外循环后肺损伤保护作用的临床研究[J].中国中西医结合杂志,2009；29(5)：414-417
[130]张锐,赵海蓉,崔鹏,等.痰热清注射液治疗严重脓毒症的临床观察[J].医药论坛杂志,2010；31,(13)：147-148
[131]徐志威.痰热清注射液治疗全身炎症反应综合征43例疗效观察[J].中国现代药物应用,2010；4(11)：116-117
[132]王波涌,张宗林,郭鹏程.痰热清注射液对急性胰腺炎肺损伤的疗效观察[J].中国药师,2006；9(3)：225
[133]黄登鹏,彭卫平,陈少武,等.痰热清注射液治疗重症急性胰腺炎抗炎作用观察[J].中国中医急症,200514(2)：117
[134]黄登鹏,彭卫平.痰热清注射液对多器官功能障碍综合症患者细胞因子表达的影响[J].中国中医急症,200615(4)：347
[135]吴伟胜,林宏.中药灌肠结合西药治疗急性呼吸窘迫综合征50例疗效观察[J].新中医,2004；34(5)：20-21
[136]梁战海.血必净注射液治疗创伤所致急性肺损伤效果观察[J].实用心脑肺血管杂志,2012；20(1)：111-112
[137]陈齐红,郑瑞强,林华,等.血必净注射液对急性呼吸窘迫综合征患者预后影响的前瞻性随机对照临床研究[J].中国危重病急救医学,2009；21(7)：405-408
[138]谢玉宝,梁子敬,黄伟青.急性肺损伤的中医药治疗进展[J].实用临床医药杂志,2008；12(2)：113-115
[139]李建生.中医药治疗急性肺损伤的研究进展[J].中国中西医结合急救杂志,1999;6(11)：523-524
[140]卢军锋,顾勤,刘宁.中医药在急性呼吸窘迫综合征诊疗中的应用[J].吉林中医药,2008；28(4)：243-245
[141]屠燕捷,郭永洁,杨爱东.中医不同治法治疗内毒素致急性肺损伤的实验研究进展[J].陕西中医,2008；29(4)：508-509
[142]田德禄.中医内科学[M].北京：人民卫生出版社.2002：78
[143]曹书华,王今达,李银平.从“菌毒并治”到“四证四法”——关于中西医结合治疗多器官功能障碍综合征辨证思路的深入与完善[J].中国危重病急救医学,2005;17(11)：641-643
[144]苏景深,刘恩顺,孙增涛.不同治法对ALI/ARDS大鼠炎性相关因子作用的影响[J].时珍国医国药,2011;22(3)：736-738
[145]刘恩顺,苏景深,孙增涛,等.通腑泻肺法对ALI/ARDS大鼠免疫炎症损伤影响的实验研究[J].天津中医药,2011；28(2)97-99
[146]谢晓华,杨银芬,张晓清,等.通腑泻热方对胸科急性肺损伤患者细胞因子的影响[J].广州中医药大学学报,2008；25(4)：294-296
[147]Wilmore D W, Smith R J,O'Dwyer S T, et al. The gut:a central organ after surgical stress [J]. Surgery,1988; 104(5):917-923
[148]李志军,李银平.肺与大肠相表里学说与多器官功能障碍综合征[J]. 中国中西医结合急救杂志,2004；11(3)：131-132
[149]万霞,刘建平.临床试验中的随机分组方法[J].中医杂志,2007；48(3)：216-219.
[150]倪宗瓒,曹素华,骆福添,等.卫生统计学[M].北京：人民卫生出版社,2004,第4版：267
[151]李琦,钱桂生,张青,等.不同剂量脂多糖对大鼠急性肺损伤效应的观察[J].第三军医大学学报,2004；26(10)：871-873
[152]黄继汉,黄晓晖,陈志扬,等.药理试验中动物间和动物与人体间的等效剂量换算[J].中国临床药理学与治疗学,2004；9(9)：1069-1072
[153]李澎涛,张娜,朱晓磊,等.痰热清注射液抗内毒素所致急性肺损伤的实验研究[J].中国药学杂志,2005；40(7)：518-521
[154]韦炳华,陈清.痰热清注射液的不良反应分析[J].中国医药导报,2011；8(1)：134-135
[155]李彬,李淑君.TNF—α和NF—κB在急性肺损伤中的作用机制[J].包头医学 院学报,2011；27(2)：120-121
[156]邢海波,李刚,徐亚平,等.内毒素性急性肺损伤大鼠肺组织中氧化指标的变化[J].实用医学杂志,2009；25(12)：1934-1936
[157]樊毫军,刘书盈,张健鹏,等.静脉注射内毒素致大鼠急性肺损伤模型的病理生理学指标评价[J].中国危重病急救医学,2006；18(8)：485-487